Casey C. Kopczynski
Keine laufenden Positionen mehr
Profil
Casey C.
Kopczynski was the founder of Aerie Pharmaceuticals, Inc. founded in 2005, where he held the title of Chief Innovation Officer in 2022.
He previously worked as Director-Research at Exelixis, Inc. from 1996 to 2002, Vice President-Research at Ercole Biotech, Inc. in 2003, and as Managing Partner at Biotech Initiative LLC from 2002 to 2005.
Dr. Kopczynski earned a doctorate degree from Indiana University.
Ehemalige bekannte Positionen von Casey C. Kopczynski
Unternehmen | Position | Ende |
---|---|---|
AERIE PHARMACEUTICALS, INC. | Gründer | 21.11.2022 |
Biotech Initiative LLC | Corporate Officer/Principal | - |
Ercole Biotech, Inc.
Ercole Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sarepta Therapeutics, Inc., Ercole Biotech, Inc. develops splice switching drugs for the treatment of major human diseases. The company is based in Research Triangle Park, NC. The company was founded by Jorn Gorlach. Ercole Biotech was acquired by Sarepta Therapeutics, Inc. on March 20, 2008 for $8.25 million. | Technik-/Wissenschafts-/F&E-Leiter | - |
EXELIXIS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2002 |
Ausbildung von Casey C. Kopczynski
Indiana University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
EXELIXIS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
Ercole Biotech, Inc.
Ercole Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sarepta Therapeutics, Inc., Ercole Biotech, Inc. develops splice switching drugs for the treatment of major human diseases. The company is based in Research Triangle Park, NC. The company was founded by Jorn Gorlach. Ercole Biotech was acquired by Sarepta Therapeutics, Inc. on March 20, 2008 for $8.25 million. | Commercial Services |
Biotech Initiative LLC |